Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 14/20 | 0.67 |
| ▸ | S1PR3 | Q99500 | 14/20 | 0.67 |
| ▸ | FAAH | O00519 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17302129 | 0.96 | S1PR1 (0.70) | S1PR1S1PR3FAAHHPGDPOLB | |
| SCHEMBL17295234 | 0.93 | S1PR1 (0.67) | S1PR1S1PR3FAAHHPGDPOLB | |
| SCHEMBL17295236 | 0.93 | S1PR1 (0.67) | S1PR1S1PR3FAAHHPGDPOLB | |
| SCHEMBL17295245 | 0.90 | S1PR1 (0.63) | S1PR1S1PR3FAAHHPGDPOLB | |
| SCHEMBL17295244 | 0.90 | S1PR1 (0.63) | S1PR1S1PR3FAAHHPGDPOLB | |
| SCHEMBL17295262 | 0.90 | S1PR1 (0.57) | S1PR1S1PR3FAAHHPGDPOLB | |
| SCHEMBL17295261 | 0.90 | S1PR1 (0.57) | S1PR1S1PR3FAAHHPGDPOLB | |
| SCHEMBL17302133 | 0.89 | S1PR1 (0.63) | S1PR1S1PR3HPGDPOLBKMT2A | |
| SCHEMBL19107400 | 0.87 | S1PR1 (0.62) | S1PR1S1PR3FAAHHPGDPOLB | |
| SCHEMBL17295558 | 0.85 | THRB (0.58) | S1PR1S1PR3KMT2ANPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4011879-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | Universität Bern (CH) | 2022-06-15 | — | — | EP | disclosed |
| EP-3148990-B1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIV BERN (CH) | 2022-01-19 | — | — | EP | disclosed |
| US-10155754-B2 | Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors | UNIVERSITAT BERN (CH) | 2018-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155754-B2 | Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors | CNR2, CNR1, GPR18 | S1PR1 211/4885S1PR3 227/4885FAAH 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.